Hydrazinobenzoylcurcumin inhibits androgen receptor activity and growth of castration-resistant prostate cancer in mice

There is a critical need for therapeutic agents that can target the amino-terminal domain (NTD) of androgen receptor (AR) for the treatment of castration-resistant prostate cancer (CRPC). Calmodulin (CaM) binds to the AR NTD and regulates AR activity. We discovered that Hydrazinobenzoylcurcumin (HBC...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Wu, Min, Kim, Sahn-Ho, Datta, Indrani, Levin, Albert, Dyson, Gregory, Li, Jing, Kaypee, Stephanie, Swamy, M. Mahadeva, Gupta, Nilesh, Kwon, Ho Jeong, Menon, Mani, Kundu, Tapas K., Reddy, G. Prem-Veer
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2015
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4467427/
https://ncbi.nlm.nih.gov/pubmed/25704883
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados